Key Elements of TMRC

• Shared risk: £50m over 5 years from Wyeth & SE (from Apr-06)
  
  
• Shared solutions: scientists / clinicians working together with Wyeth translational scientists to develop solutions and deliver project outputs
  
  
• Shared management: via Scientific Review Board and Steering Committee with senior level representation (VP, head of school)
  
  
• Shared ownership: IP jointly owned, agreed exploitation, royalty terms
  
  
• Priority therapeutic areas: CVMD, oncology, neuroscience, inflammation, women’s health, musculoskeletal
  
  
• Flexible: Uni/NHS partner combinations for each project (6-24 months)
  
  
• Core laboratory: deliver industry-standard biomarker validation
  
  
• Core staff: dedicated resources at each Uni/NHS to drive TMRC locally
  
  
• TMRI Ltd: private company managing overall implementation of TMRC and exploitation of non-therapeutic IP